Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
企業コードBHC
会社名Bausch Health Companies Inc
上場日Sep 20, 1994
最高経営責任者「CEO」Appio (Thomas J)
従業員数20700
証券種類Ordinary Share
決算期末Sep 20
本社所在地2150 St. Elzear Blvd. West
都市LAVAL
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国Canada
郵便番号H7L 4A8
電話番号18003611448
ウェブサイトhttps://www.bauschhealth.com/
企業コードBHC
上場日Sep 20, 1994
最高経営責任者「CEO」Appio (Thomas J)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし